Insights

Oral Peptide Platform Arecor is actively developing a novel oral delivery platform for peptides, including GLP-1 receptor agonists, targeting obesity and diabetes markets. This presents a potential collaboration or licensing sales opportunity with partners seeking non-invasive, patient-friendly delivery solutions.

Clinical-Stage Growth As a clinical-stage biotechnology company with ongoing Phase 2 discussions and FDA interactions for AT278, there are multiple opportunities to engage in funding partnerships, strategic alliances, or co-development deals with biopharma players looking for late-stage or near-term asset value creation.

Formulation Partnerships Arecor has a track record of formulation development collaborations, including higher-concentration formulations for obesity therapies and peptide therapies. This indicates a ready-made channel for CDMO or pharma partners seeking optimized formulations to improve efficacy, dosing, or stability.

Partnership Network Recent collaborations with Skye Bioscience and an unnamed biopharma partner, plus participation in industry conferences, suggests an active partner ecosystem. There are sales openings for licensing, co-development, or milestone-based partnerships with mid-sized biopharma players seeking injectable-to-oral or enhanced-peptide solutions.

Commercial Readiness With revenue in the low single-digit millions and funding around tens of millions, Arecor may be seeking strategic investors or collaboration partners to accelerate late-stage development, manufacturing scale-up, and potential product launches in cardiometabolic indications aligned with obesity and diabetes.

Similar companies to Arecor Therapeutics

Arecor Therapeutics Tech Stack

Arecor Therapeutics uses 8 technology products and services including iCIMS, Cloudflare, WordPress, and more. Explore Arecor Therapeutics's tech stack below.

Media & News

Arecor Therapeutics's Email Address Formats

Arecor Therapeutics uses at least 2 email formats:
Arecor Therapeutics Email FormatsExamplePercentage
First.Last@arecor.comJohn.Doe@arecor.com
99%
First.Middle.Last@arecor.comJohn.Michael.Doe@arecor.com
1%

Frequently Asked Questions

What is Arecor Therapeutics's phone number?

Minus sign iconPlus sign icon
You can contact Arecor Therapeutics's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Arecor Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Arecor Therapeutics's official website is arecor.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Arecor Therapeutics generate?

Minus sign iconPlus sign icon
As of October 2026, Arecor Therapeutics's annual revenue is estimated to be $1M - $10M.

What is Arecor Therapeutics's SIC code and NAICS code?

Minus sign iconPlus sign icon
Arecor Therapeutics's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Arecor Therapeutics have currently?

Minus sign iconPlus sign icon
As of October 2026, Arecor Therapeutics has approximately 35 employees across 2 continents, including Europe and North America. Key team members include Chief Executive Officer: S. H., Chief Scientific Officer: J. J. and Chief Financial Officer: D. E. Explore Arecor Therapeutics's employee directory with LeadIQ.

What industry does Arecor Therapeutics belong to?

Minus sign iconPlus sign icon
Arecor Therapeutics operates in the Biotechnology Research industry.

What technology does Arecor Therapeutics use?

Minus sign iconPlus sign icon
Arecor Therapeutics's tech stack includes iCIMS, Cloudflare, WordPress, Shopify, Microsoft 365, Google Cloud, DocuSign and WP Engine.

What is Arecor Therapeutics's email format?

Minus sign iconPlus sign icon
Arecor Therapeutics's email format typically follows the pattern of First.Last@arecor.com. Find more Arecor Therapeutics email formats with LeadIQ.

How much funding has Arecor Therapeutics raised to date?

Minus sign iconPlus sign icon
As of October 2026, Arecor Therapeutics has raised $42M in funding. The last funding round occurred on Oct 25, 2025 for $7M.

When was Arecor Therapeutics founded?

Minus sign iconPlus sign icon
Arecor Therapeutics was founded in 2007.
Arecor Therapeutics logo

Arecor Therapeutics

Biotechnology ResearchEngland, United Kingdom11-50 Employees

Arecor Therapeutics is a clinical-stage biotechnology company developing therapies for diabetes, obesity and other cardiometabolic diseases, with the goal of reducing treatment burden and improving outcomes. It is based in Little Chesterford, England, in the East of England region, and operates as a small-to-mid-sized enterprise focused on translational research and clinical development. The company sits within the biotechnology research industry, pursuing approaches that seek to enhance existing therapies through novel formulations. Its work is centered on bringing forward therapeutics intended to address unmet needs in metabolic health.

In 2025, Arecor announced a formulation development collaboration with Skye Bioscience to produce a higher-concentration formulation of nimacimab, an investigational CB1 inhibitor for obesity. It has also indicated participation in industry events, including an upcoming presentation at the Oppenheimer Annual Healthcare Medtech & Services Conference in March 2026.

Section iconCompany Overview

Phone number
Website
arecor.com
SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2007
Employees
11-50

Section iconFunding & Financials

  • $42M

    Arecor Therapeutics has raised a total of $42M of funding over 12 rounds. Their latest funding round was raised on Oct 25, 2025 in the amount of $7M as a Post IPO Debt.

  • $1M - $10M

    Arecor Therapeutics's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.